EUVIMEDEUVIMED entdecken
Open Access

Clinical value of [ 18 F]AlF-Thretide PET/CT and early-time-point PET acquisition in the detection and staging of prostate cancer

Xin Cheng, Guozhu Hou, Mingshuai Wang, Shan Zheng, Wei Yao, Xuejuan Wang, Rong Zheng, Nianzeng Xing, Jingjing Zhang

Theranostics · 2025

DOI: 10.7150/thno.103667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2025. Verfasst von Xin Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Recent studies have demonstrated the potential of PET/CT with 18F-labeled ligands targeting prostate-specific membrane antigen (PSMA), as a promising method for prostate cancer (PCa) management. The aim of this study is to assess the clinical value of [18F]AlF-Thretide ([18F]AlF-PSMA-BCH) PET/CT and early time-point PET acquisition for detecting and staging PCa. Materials and Methods: From November 2022 to May 2023, a total of 73 PCa patients were included in our study. Along with whole-body PET/CT conducted at a median time of 76 min (range: 59-139 min) post-injection, a single-bed pelvic early PET/CT scan was performed, starting at a median time of 187 s (range: 161-453 s) post-injection. Visual analysis of the images was performed first, followed by semiquantitative analysis of maximum standardized uptake value (SUVmax) of primary PCa lesions, metastases, bladder, and surrounding tissues on both early and routine time-point PET/CT scans.

Results

Among 56 non-surgical patients (either treatment-naive or after androgen deprivation therapy only) who had previously undergone conventional imaging, N staging was revised in 4 cases, and M staging in 2 cases. In 54 patients with bone scans for comparison, 111 lesions on [18F]AlF-Thretide PET/CT and 41 lesions on bone scans were identified as indicative of bone metastases. The median tumor-to-bladder (T/BL) ratios for primary lesions increased from 0.33 (range: 0.03-6.22) on routine time-point PET/CT to 4.66 (range: 0.24-645.00) on early time-point PET/CT. In 94.6% (53/56) of patients, the T/BL ratios were higher on early PET/CT scans than on routine time-point PET/CT scans. However, the SUVmax of surrounding tissues was found to be higher on early PET/CT scans compared to routine PET/CT scans (external iliac vessels: 8.02 ± 1.64 vs. 2.66 ± 0.59; inferior vesical artery branches near the prostate: 4.70 ± 1.09 vs. 2.30 ± 0.49; gluteus maximus muscle: 1.19 ± 0.31 vs. 0.80 ± 0.25). Of the 17 patients who underwent surgery prior to PET/CT, early PET/CT scans improved the detection rate of local recurrences from 2/17 to 5/17. Conclusion: [18F]AlF-Thretide PET/CT was shown to be a valuable imaging modality in the management of patients with PCa. Early PET/CT scans can improve the detection rate of local recurrences and provide additional information for lesions that are challenging to distinguish from urinary uptake on routine PET/CT scans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyHumansMaleAgedMiddle AgedNeoplasm StagingFluorine RadioisotopesAged, 80 and overRadiopharmaceuticals

Stichwörter der Autor:innen

PET imaging[18F]AlF-Thretideearly scanprostate cancer (PCa)prostate-specific membrane antigen (PSMA)

Substanzen

Fluorine RadioisotopesFluorine-18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021,…
  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, Chi…
  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Theranostics Center of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, 11 Biopolis Way, Helios, Singapore, 138667, Singapore.

Zitieren

APA

Cheng, X., Hou, G., Wang, M., Zheng, S., Yao, W., Wang, X., Zheng, R., Xing, N., & Zhang, J. (2025). Clinical value of [ 18 F]AlF-Thretide PET/CT and early-time-point PET acquisition in the detection and staging of prostate cancer. Theranostics. https://doi.org/10.7150/thno.103667

Vancouver

Cheng X, Hou G, Wang M, Zheng S, Yao W, Wang X, et al. Clinical value of [ 18 F]AlF-Thretide PET/CT and early-time-point PET acquisition in the detection and staging of prostate cancer. Theranostics. 2025. doi:10.7150/thno.103667

BibTeX
@article{Cheng2025,
  author = {Cheng, Xin and Hou, Guozhu and Wang, Mingshuai and Zheng, Shan and Yao, Wei and Wang, Xuejuan and Zheng, Rong and Xing, Nianzeng and Zhang, Jingjing},
  title = {Clinical value of [ 18 F]AlF-Thretide PET/CT and early-time-point PET acquisition in the detection and staging of prostate cancer},
  journal = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.103667}
}
Kostenlos starten →